Randomized Phase II Trial Comparing New Treatments to Standard Therapy in Adults with Relapsed or Refractory Follicular Lymphoma
Led by University of Birmingham · Updated on 2026-05-05
284
Participants Needed
25
Research Sites
130 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating new treatments for patients with relapsed or refractory follicular lymphoma, aiming to find better options than the current standard therapies. This Phase II trial compares experimental therapies to standard treatments chosen by doctors before the trial. The study focuses on how patients respond to treatment, measured by PET scans after 24 weeks, to identify therapies that may improve outcomes.
Patients will be randomly assigned to receive either an experimental treatment or one of five standard therapy options, such as RCHOP or bendamustine with rituximab. In the first treatment round, patients may receive epcoritamab by weekly injection combined with oral lenalidomide in 28-day cycles, up to 12 cycles. Subsequent rounds will test other new treatments, with patients more likely to receive the experimental option. The trial plans to enroll 284 patients and follow them for up to 10 years.
Participants will undergo assessments including PET-CT scans, blood tests, and quality of life questionnaires before and during treatment. Researchers will track treatment responses, survival, adverse effects, and quality of life over the study period. After treatment, patients will be followed yearly to monitor long-term outcomes and any new treatments needed, with total participation lasting up to a decade.
CONDITIONS
Brief Title
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Research Team
T
Trial Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Biopsy proven relapsed or refractory CD20 positive, grade 1-3a follicular lymphoma within 3 months prior to trial entry
Age 18 years or older
Advanced disease requiring treatment as judged by treating physician
Suitable for standard available therapy as determined by Investigator
Prior treatment with at least one line of immunochemotherapy
Assessable disease by PET-CT with at least one involved node >1.5cm or extranodal lesion >1cm
ECOG performance status of 0, 1, or 2 at trial entry
Adequate organ function including ANC ≥ 1.0 x 10^9/L, platelet count ≥ 75 x 10^9/L (or ≥ 50 x 10^9/L if bone marrow infiltration or splenomegaly), ALT and AST ≤ 3 x ULN, direct bilirubin ≤ 2 x ULN unless Gilbert's syndrome, CrCl ≥ 50 mL/min, PT, INR and aPTT ≤ 1.5 x ULN unless anticoagulated, and normal LVEF
Able to provide written informed consent
Women of childbearing potential and partners must use effective contraception
You will not qualify if you...
Transformation to high grade lymphoma within past year, including grade 3b follicular lymphoma
Non-FDG avid disease
Prior allogenic stem cell or solid organ transplant
Prior treatment with lenalidomide
CAR-T therapy within 100 days prior to trial treatment
Planned stem cell transplant or maintenance therapy within 24 weeks of starting treatment
Planned immunochemotherapy with platinum-containing regimen
Known HIV positivity or uncontrolled hepatitis C infection
Hepatitis B surface antigen positive or detectable viral DNA
Other malignancy within 2 years except certain early-stage or non-invasive cancers
Active systemic infection requiring treatment
Current or prior lymphoma involvement of central nervous system
History of allergy or anaphylaxis to anti-CD20 monoclonal antibody therapy
Known hypersensitivity to experimental or control arm medications
Serious medical or psychiatric illness interfering with participation
Recent cancer treatment within 4 weeks or systemic steroids within 7 days prior to treatment
Unwillingness to use contraception during and up to 12-18 months after treatment
Pregnant or breastfeeding women
Prior treatment with the experimental therapy under investigation
Major surgery within 30 days prior to treatment
Severe heart conditions related to planned treatments
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Round 1 Treatment
Duration - Up to 12 cycles of 28 days each
Participants receive up to 12 cycles of treatment with either the experimental therapy (epcoritamab and lenalidomide) or investigator choice standard therapy. Epcoritamab is given as weekly subcutaneous injections during cycles 1 and 2, then on day 1 of cycles 3-12. Lenalidomide is taken orally on days 1 to 21 of each 28-day cycle.
Weekly visits during cycles 1 and 2, then visits on day 1 of cycles 3 to 12
Rounds 2 and 3 Treatment
Duration - Sequential treatment rounds following Round 1; exact durations to be confirmed
Participants may receive experimental treatments in rounds 2 and 3. Details of these treatments will be provided when available. Investigator choice standard therapy is also an option in these rounds.
Visits as per treatment schedule in rounds 2 and 3 (details to be confirmed)
Follow-up
Duration - Up to 10 years
After completing treatment rounds, participants are followed up yearly to monitor long-term outcomes including survival and response to therapy.
Yearly visits for follow-up assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Similar Trials
Phase 1 Study of BAFFR-Targeting CAR T-Cell Therapy with Chemotherapy for Relapsed or Refractory B-Cell Blood Cancers
Evaluation of Brentuximab Vedotin and Bendamustine Combination Therapy for Relapsed or Resistant Follicular Lymphoma
Phase II Study of Haploidentical Donor Stem Cell Transplant Using Treosulfan, Fludarabine, and Total-Body Irradiation for Blood Cancers
Study of Pirtobrutinib and Mosunetuzumab to Treat Adults With Relapsed or Refractory Grade 1 to 3a Follicular Lymphoma
Phase I Study of Q702, an Oral Immunomodulatory Drug, for Treating Blood Cancers and Related Diseases
Randomized Phase II Trial Comparing New Treatments to Standard Therapy in Adults with Relapsed or Refractory Follicular Lymphoma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.